NEWS DETAIL

FDA D.I.S.C.O. Burst Edition: FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer

Listen to a soundcast of the May 31, 2023, FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer.”

Información médica July 4, 2026

该文章暂未提取到完整正文，已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。

Productos relacionados con este articulo

Estos productos se asociaron automaticamente a partir del titulo, el resumen y el contenido del articulo.

Preguntas frecuentes

Which products are related to this article?

The system matched these relevant products from the article content: OLADX Olaparib Lucius Olaparib – Comprar en línea OLADX Olaparib.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.